1 Warren Buffett Stock That Should Be on Your Buy List This Fall

NYSE: JNJ | Johnson & Johnson News, Ratings, and Charts

JNJ – Investors can take a cue from Warren Buffet’s portfolio and consider buying the popular healthcare name Johnson & Johnson (JNJ), as it is expected to weather any possible economic conditions in the upcoming months, thanks to its strong fundamentals, almost inelastic demand for its products, and strong brand recognition worldwide. Read more….

Warren Buffet, the Oracle of Omaha, has created exceptional wealth through his investments. Investors widely follow the billionaire’s stock picks. Healthcare giant Johnson & Johnson (JNJ - Get Rating) happens to be one of his holdings.

For investors looking for stocks that are long-term wealth creators, JNJ could be a perfect fit. In addition to capital appreciation, the company shared its profits periodically with investors as dividends for 59 years.

Persistently high inflation and the Fed’s aggressive interest rate hikes have led to recession fears and triggered a broad-based sell-off in various asset classes. However, JNJ has been able to survive the market conditions well because of the defensive nature of its business and sound fundamentals.

Healthcare stocks are well known for their stability during economic uncertainties. That’s because, irrespective of the economic cycles, the healthcare industry witnesses stable demand.

JNJ surpassed consensus EPS and revenue estimates in the third quarter (ended September 2022). Its EPS beat analyst estimates by 2.6%, and its revenue surpassed the consensus EPS estimate by 1.5%. CEO Joaquin Duato said, “Our third quarter performance demonstrates our continued strength and resilience across all three of our businesses.”

“Through the ongoing efforts of our teams around the world, we continue to navigate the dynamic macroeconomic environment and remain focused on delivering transformative healthcare solutions,” he added.

JNJ is expected to create more value for its shareholders as it hives off its consumer health segment, which includes various self-care, skin health/beauty, and essential products, into a separate company. The consumer health segment has reported a decline of 0.4% year-over-year compared to the MedTech and Pharmaceutical Products segments, with 2.1% and 2.6% year-over-year growth, respectively.

For fiscal 2022, the company expects its operational sales to come between $97.50 billion to $98 billion, while its adjusted operating EPS is expected to arrive between $10.70 and $10.75. JNJ CEO Joaquin Duato said, “Looking ahead, I remain confident in our business and ability to continue advancing our innovative portfolio and pipeline.”

JNJ’s revenue has grown at a CAGR of 5.5% over the past three years. The company’s EBITDA grew at a CAGR of 4.6% over the past three years.

With the kind of cash the company generates, JNJ can easily opt for organic and inorganic expansion, which will spearhead the company’s growth in the long term. On November 1, 2022, JNJ announced that it had entered into a definitive agreement to acquire Abiomed. The transaction is expected to broaden Johnson & Johnson MedTech’s (JJMT) position as a growing cardiovascular innovator.

CEO Joaquin Duato said, “The addition of Abiomed is an important step in executing our strategic priorities, and our vision for the new Johnson & Johnson focused on Pharmaceutical and MedTech. We have committed to enhancing our position in MedTech by entering high-growth segments. The addition of Abiomed provides a strategic platform to advance breakthrough treatments in cardiovascular disease and helps more patients worldwide while driving value for our shareholders.”

JNJ four-year average dividend yield is 2.60%, and its forward annual dividend of $4.52 translates to a 2.62% yield. Its dividend has grown at a 5.7% CAGR over the past three years.

The stock has gained 0.8% in price year-to-date and 6.1% over the past year to close the last trading session at $172.45.

Here’s what could influence the performance of JNJ in the upcoming months:

Solid Financials

JNJ’s sales increased 1.9% year-over-year to $23.79 billion for the third quarter ended September 30, 2022. The company’s net earnings increased 21.6% year-over-year to $4.45 billion. Also, its EPS came in at $1.68, representing an increase of 22.6% year-over-year.

Favorable Analyst Estimates

Analysts expect JNJ’s EPS for fiscal 2022 and 2023 to increase 2.5% and 3.2% year-over-year to $10.04 and $10.37, respectively. Its revenue for fiscal 2022 and 2023 is expected to increase 1.3% and 2.6% year-over-year to $95.04 billion and $97.55 billion, respectively. It surpassed Wall Street EPS estimates in each of the trailing four quarters.

Mixed Valuation

In terms of forward non-GAAP P/E, JNJ’s 17.17x is 5% lower than the 18.08x industry average. Likewise, its 15.28x forward EV/EBIT is 7% lower than the 16.43x industry average.

However, its 4.39x forward non-GAAP PEG is 163.4% higher than the 1.66x industry average. Also, its 4.74x forward P/S is 15% higher than the 4.13x industry average.

High Profitability

In terms of trailing-12-month gross profit margin, JNJ’s 67.52% is 24.3% higher than the 54.31% industry average. Likewise, its 0.54% trailing-12-month asset turnover ratio is 55.9% higher than the industry average of 0.35%. 

Furthermore, the stock’s trailing-12-month ROCE and ROA came in at 26.45% and 10.94%, respectively, compared to the negative industry averages.

POWR Ratings Show Promise

JNJ has an overall rating of A, equating to a Strong Buy in our POWR Ratings system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.

Our proprietary rating system also evaluates each stock based on eight distinct categories. JNJ has a C grade for Value, consistent with its mixed valuation.

It has a B grade for Quality, in sync with its high profitability. The stock has a 0.57 beta, justifying its A grade for Stability.

JNJ is ranked #4 out of 164 stocks in the Medical – Pharmaceuticals industry. Click here to access JNJ’s Growth, Momentum, and Sentiment ratings.

Bottom Line

JNJ is a core part of Warren Buffet’s portfolio as it has not only delivered returns through capital appreciation but has also shared its profits with shareholders as dividends. The company has been consistently growing its revenues and earnings, and analysts expect it to keep growing its top and bottom-line numbers over the next two years.

Moreover, with JNJ hiving off its consumer health segment into a separate entity, the stock is expected to become even more attractive. Also, the acquisition of Abiomed will help it enter the high-growth cardiovascular space. Given its robust financials, higher-than-industry profitability, and stable dividend payouts, it could be a solid investment this fall.

How Does Johnson & Johnson (JNJ) Stack up Against Its Peers?

JNJ has an overall POWR Rating of A, equating to a Strong Buy rating. Check out these other stocks within the Medical – Pharmaceuticals industry with an A (Strong Buy) rating: Novo Nordisk A/S (NVO - Get Rating), Roche Holding AG (RHHBY - Get Rating), and Neurocrine Biosciences, Inc. (NBIX - Get Rating).

Want More Great Investing Ideas?

3 Stocks to DOUBLE This Year


JNJ shares were trading at $173.98 per share on Thursday afternoon, up $1.53 (+0.89%). Year-to-date, JNJ has gained 3.70%, versus a -16.62% rise in the benchmark S&P 500 index during the same period.


About the Author: Dipanjan Banchur


Since he was in grade school, Dipanjan was interested in the stock market. This led to him obtaining a master’s degree in Finance and Accounting. Currently, as an investment analyst and financial journalist, Dipanjan has a strong interest in reading and analyzing emerging trends in financial markets. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
JNJGet RatingGet RatingGet Rating
NVOGet RatingGet RatingGet Rating
RHHBYGet RatingGet RatingGet Rating
NBIXGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Stock Market Update: It’s Complicated!

The S&P 500 (SPY) may have bounced 17% from recent lows, but the outlook for stocks from here is...in a word...COMPLICATED. Read on to get Steve Reitmeister full market outlook and trading plan for this complicated market environment.

Becoming More Bullish on Stocks, But...

Stocks are on a roll with the S&P 500 (SPY) up more than 10% from the recent lows. Before you start getting too giddy, you should read this updated market outlook and trading plan Steve Reitmeister.

Stock Market Held Hostage

Uncertainty is the term most often applied to this stock market. Uncertainty over tariffs. Uncertainty of whether the S&P 500 (SPY) will fall into bear territory. Uncertainty over what happens next. Steve Reitmeister dives into the uncertainty to make sense of the market in this week’s commentary...

Stock Market Standing on the 50 Yard Line

Steve Reitmeister contemplates where the stock market stands now and what happens next in trying to stay on the right side of the market action. One path points to bear and one to new highs for the S&P 500 (SPY). Which will it be?

Bear or Bull Market?

The S&P 500 is on the brink of bear market territory...but that outcome is not a given at this time. Steve Reitmeister shares insights gleaned from his 45 years of investing to shine a light on current conditions along with his top picks...

Read More Stories

More Johnson & Johnson (JNJ) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All JNJ News